Expression of PD-L1 in tumour cells and infiltrating immune cells and PD-1 in tumour-infiltrating T cells has been associated with responsiveness to blockade of this immune checkpoint1, 7, 8, 9, 10; however, mechanisms of both de novo and adaptive resistance to therapy are unclear. The gene discussed is CD274; the disease is neoplasm.